First therapeutic drug monitoring of experimental favipiravir in Borna disease virus 1 (BoDV-1) encephalitis patients reveals significant gaps in antiviral treatment: a pilot investigation
In conclusion, monitoring experimental FPV therapy in BoDV-1 encephalitis is feasible and should be performed continuously. Future prospective in-depth (multicenter) studies should include more patients and focus on dose-finding, dose-response relationships, and define a therapeutic index to improve outcomes of this so far nearly uniformly fatal disease.
Authors
- Victoria Lieftüchter
- Alice Ewert
- Simone C. Tauber (ORCID: https://orcid.org/0000-0001-9149-3071)
- Leonie Grosse (ORCID: https://orcid.org/0000-0001-6277-3218)
- Petra Allartz
- Michael Vogeser (ORCID: https://orcid.org/0000-0002-2745-2475)
- Michael Paal (ORCID: https://orcid.org/0000-0001-8831-0238)
- Dennis Tappe (ORCID: https://orcid.org/0000-0002-4493-0395)
- Katharina Habler (ORCID: https://orcid.org/0000-0002-5110-346X)
- Kirsten Pörtner (ORCID: https://orcid.org/0000-0001-8191-8056)
- Johannes Schiefer
Institutions
- Robert Koch Institute (DE)
- Universitätsklinikum Aachen (DE)
- Ludwig-Maximilians-Universität München (DE)
- RWTH Aachen University (DE)
- Bernhard Nocht Institute for Tropical Medicine (DE)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-10-04
- DOI
- https://doi.org/10.1186/s40001-025-03117-x
- Primary Topic
- Virology and Viral Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00